Denodo Achieves Databricks Validated Partner Status for Its Seamless Integration in Support of AI and Analytics Leave a reply Working Together, Both Technologies Enable Greater Trust and Agility for Joint Customers PALO ALTO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Denodo, a leader in data management, announced that it has achieved the Databricks Validated Partner designation, reinforcing the growing collaboration between the two companies to help enterprises accelerate AI and analytics on governed, trusted data. The Denodo Platform, a logical data management solution, underwent rigorous technical validation by Databricks, assessing its compatibility, interoperability, performance, and security alignment with the Databricks

iHerb Kicks Off Global Gifting Season with its Annual Black Friday and Cyber Monday Sales Event Leave a reply Wellness and Beauty Take Center Stage for Month-Long Promotions Featuring Discounts Starting at 20% Off iHerb Kicks Off Global Gifting Season iHerb, one of the world’s leading online retailers for health and wellness, launched its premier holiday event: Black Friday. This month-long celebration of savings is available to customers worldwide, giving shoppers ample time to secure essential vitamins, supplements, beauty products, sports nutrition, grocery items, and more. IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — iHerb, one of the world’s leading

SASE OpsLab Partners with Netskope to Revolutionize SASE Deployment at Scale for Frictionless Customer Experience Leave a reply Integration uses prepackaged automation to make large-scale SASE rollouts faster, easier, and inherently more secure through error-free tunnel orchestration DUBLIN, Nov. 12, 2025 (GLOBE NEWSWIRE) — UBiqube, the leader in multi-domain IT infrastructure orchestration and automation, today announced the expansion of its SASE OpsLabs enablement portal with Netskope, a leader in modern security and networking for the cloud and AI era. The new integration introduces automation kits for deployment and migration use cases, providing Fortune 5000 companies with a faster and highly

NeOnc Technologies Reports Updated Clinical Results Leave a reply Results of Clinical Trials Provide Evidence Supporting Significant Radiographic Response and Potential Long-Term Survival in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100 CALABASAS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi–Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers today announced updated clinical results from its current Phase 1/2a and compassionate care studies involving a cohort of 24 patients with recurrent WHO Grade III/IV isocitrate dehydrogenase 1 (IDH1)–mutant astrocytoma treated with its investigational intranasal

NeOnc Technologies Reports Updated Clinical Results Leave a reply Results of Clinical Trials Provide Evidence Supporting Significant Radiographic Response and Potential Long-Term Survival in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100 CALABASAS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi–Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers today announced updated clinical results from its current Phase 1/2a and compassionate care studies involving a cohort of 24 patients with recurrent WHO Grade III/IV isocitrate dehydrogenase 1 (IDH1)–mutant astrocytoma treated with its investigational intranasal

NeOnc Technologies Reports Updated Clinical Results Leave a reply Results of Clinical Trials Provide Evidence Supporting Significant Radiographic Response and Potential Long-Term Survival in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100 CALABASAS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi–Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers today announced updated clinical results from its current Phase 1/2a and compassionate care studies involving a cohort of 24 patients with recurrent WHO Grade III/IV isocitrate dehydrogenase 1 (IDH1)–mutant astrocytoma treated with its investigational intranasal

NeOnc Technologies Reports Updated Clinical Results Leave a reply Results of Clinical Trials Provide Evidence Supporting Significant Radiographic Response and Potential Long-Term Survival in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100 CALABASAS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi–Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers today announced updated clinical results from its current Phase 1/2a and compassionate care studies involving a cohort of 24 patients with recurrent WHO Grade III/IV isocitrate dehydrogenase 1 (IDH1)–mutant astrocytoma treated with its investigational intranasal